ArticleWorld journal of gastroenterology2025
Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Heterogeneity, Risk Stratification, and Personalized Care.Clinical and experimental gastroenterology · 2026Review
- Comparison of Triglyceride-Glucose Index Indices and Fatty Liver Index in Predicting Metabolic Dysfunction-Associated Fatty Liver Disease: A Cross-Sectional Study Conducted in Vietnam.Life (Basel, Switzerland) · 2025Article
- MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action.Frontiers in clinical diabetes and healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is a recently proposed term that highlights the role of metabolic dysfunction in hepatic steatosis. It currently affects more than one-third of adults worldwide and is associated with liver fibrosis, hepatocellular carcinoma, cardiovascular disease, and chronic kidney disease. Given its high prevalence, asymptomatic progression, and revised definition, evaluating its epidemiology and risk profile remains an important public health priority.
aimTo assess the prevalence and characteristics of MAFLD among Vietnamese individuals undergoing health check-ups.
methodsThis retrospective study included 331 adults undergoing routine health check-ups at The Health Evaluation and Promotion Center, International University of Health and Welfare Center, Cho Ray Hospital, from June to October 2023. MAFLD was diagnosed based on the 2020 international expert consensus. Data collected included demographic, clinical, laboratory information, and metabolic risk factors from routine health check-up records. Descriptive statistics,
resultsMAFLD was identified in 97 of 331 individuals (29.31%). Prevalence was significantly higher in men than women (44.51%
conclusionMAFLD is prevalent in Vietnamese adults undergoing health screening. It is strongly associated with sex, age, body mass index, and metabolic disorders, indicating the importance of early detection and integrated management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.